Ultrasal-ER

Manufacturer
Elorac, Inc. | Swiss-American CDMO, LLC | Microconsult, Inc.
Effective date
2021-12-08
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
25
Source
full-release
Hydrated at
2026-05-31 20:38:34

Label at a glance#

ProductUltrasal-ER
Active ingredientsalicylic acid
Label structure3 sections

Label contents#

Full prescribing information#

Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution: Package Insert

SPL PATIENT PACKAGE INSERT SECTION

SPL UNCLASSIFIED SECTION

Rx only

FOR TOPICAL USE ONLY.

NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.

DESCRIPTION

DESCRIPTION SECTION

UltraSal-ER is a topical preparation containing 28.5% salicylic acid extended release in a proprietary film-forming virucidal solution composed of acrylates copolymer, butyl acetate, carthamus tinctorius seed oil, cocamidopropyl dimethylamine, ethylhexylglycerin, isopropyl alcohol, isopropyl-metacresol, olea europaea fruit oil, phenic acid, phenoxyethanol, polysorbate 80, polyvinyl butyral, trimethyl pentanyl diisobutyrate, and water. The pharmacologic activity of UltraSal-ER is generally attributed to the keratolytic activity of salicylic acid, which is incorporated into a polyacrylic, film-forming virucidal solution designed to cover the wart without the need for a bandage. The structural formula of salicylic acid is:

ultrasal-5-01.jpg
ultrasal-5-01.jpg

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Although the exact mode of action for salicylic acid in the treatment of warts is unknown, its activity appears to be associated with its keratolytic action, which results in mechanical removal of epidermal cells infected with wart viruses. UltraSal-ER incorporates a unique patented extended release form of salicylic acid that provides for enhanced release of salicylic acid for over 24 hours.

The virucidal complex incorporated into UltraSal-ER’s proprietary solution is designed to help reduce risk of reinfection at the wart site, as well as prevent viral contamination of the product under normal usage.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

UltraSal-ER is indicated for the topical treatment and removal of common warts and plantar warts.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Patients with diabetes or impaired blood circulation should not use UltraSal-ER. UltraSal-ER also should not be used on moles, birthmarks, and unusual warts with hair growing from them, or warts on the face.

PRECAUTIONS

PRECAUTIONS SECTION

UltraSal-ER is for external use only. Do not permit UltraSal-ER to contact eyes or mucous membranes. If contact with eyes or mucous membranes occurs, immediately flush with water for 15 minutes. UltraSal-ER should not be allowed to contact normal skin surrounding the wart site, since localized irritation may occur. Treatment should be discontinued if excessive irritation occurs.

UltraSal-ER is flammable. Keep away from fire or flame. Keep bottle tightly capped when not in use.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

A localized irritant reaction may occur if Ultrasal-ER is applied to the normal skin surrounding the wart. Any irritation may normally be controlled by temporarily discontinuing use and by applying the medication only to the wart site when treatment is resumed.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Prior to applying UltraSal-ER, soak wart in warm water for five minutes. Remove any loose tissue by gently rubbing with a washcloth, emery board, or pumice stone. Dry the wart site thoroughly. Using the brush applicator supplied, apply UltraSal-ER twice to the entire wart surface, allowing the first application to dry before applying the second. Continue treatment once or twice a day as directed by your healthcare provider. Be careful not to apply to surrounding skin.

Clinically visible improvement normally occurs during the first or second week of therapy. Resolution may be expected after four to six weeks of UltraSal-ER use, though some warts may take longer to remove.

HOW SUPPLIED

HOW SUPPLIED SECTION

UltraSal-ER is supplied in 10 mL amber bottles with a brush applicator (NDC 42783-323-10).

Store at 15° to 30°C (59° to 86°F).

Manufactured for:

Elorac, Inc.

Vernon Hills, IL 60061

U.S. Patent No. 6,979,440

Additional Patent Pending

© 2014 Elorac, Inc.

1/2014

211909

PATIENT INSTRUCTIONS

PATIENT MEDICATION INFORMATION SECTION

Your health care provider has prescribed UltraSal-ER, a topical prescription preparation for the treatment of common warts and plantar warts. In order for UltraSal-ER to work properly and to ensure maximum benefit, the following instructions should be followed carefully. Of course, as with any medication, always consult your health care provider if you experience any discomfort or unexpected reactions.

ultrasal-5-04.jpgultrasal-5-04.jpg

STEP 1

WASH

  • Soak wart area in warm water for about 5 minutes.
  • Remove any loose tissue using a washcloth, emery board, or pumice stone.
  • Dry thoroughly.

ultrasal-5-05.jpgultrasal-5-05.jpg

STEP 2

BRUSH

  • Using the brush applicator supplied, apply twice to entire wart surface, allowing the first application to dry before applying the second.
  • Be careful not to apply to surrounding skin.
  • Leave UltraSal-ER on wart area after it dries.

Repeat Step 1 and Step 2 once or twice daily as advised by the health care provider.

ultrasal-5-06.jpgultrasal-5-06.jpg

Clinically visible improvement will normally occur during the first or second week of therapy. Resolution may be expected after four to six weeks of UltraSal-ER use, though some warts may take longer to remove.

ultrasal-5-07.jpgultrasal-5-07.jpg

Vernon Hills, IL 60061

SPL UNCLASSIFIED SECTION

Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution:  Container Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42783-323-10

Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution

1/3 fl. oz. (10 mL)

Rx only

ultrasal-bottle-label.jpgultrasal-bottle-label.jpg

Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution: Carton Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42783-323-10

Ultrasal-ER (28.5% Salicylic Acid Extended Release) Antiviral Film-Forming Solution

1/3 fl. oz. (10 mL)

Rx only

ultrasal-carton-label.jpgultrasal-carton-label.jpg

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1487371salicylic acid 28.5 % Topical SolutionPSN25
1487376UltraSal-ER 28.5 % Wart Remover Topical SolutionPSN25
1487376salicylic acid 285 MG/ML Topical Solution [Ultrasal]SBD25
1487371salicylic acid 285 MG/ML Topical SolutionSCD25
1487371salicylic acid 28.5 % Topical SolutionSY25
1487376Ultrasal 285 MG/ML Topical SolutionSY25
1487376Ultrasal-ER 28.5 % Film-Forming Topical SolutionSY25

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
42783-323-102023-01-30C16284748780-1f386c649-cdec-0266-e053-dadaa90a7c1aa01a3ccd-d9bc-40b6-b269-cddd6d0e47c5

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
42783-323-10Ultrasal-ER10 mL in 1 BOTTLE, WITH APPLICATORSOLUTION1025
42783-323-10Ultrasal-ER1 in 1 CARTONSOLUTION125

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
42783-323ULTRASAL-ER (SALICYLIC ACID) SOLUTION [ELORAC, INC.]25Legacy NDC, 2 package rows20211209_a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
42783-323-10ML - Milliliter42783-3232369453e-1506-4e07-8bd3-19fdc0e5929d12014-05-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
salicylic acidACTIVE INGREDIENTO414PZ4LPZ2
salicylic acidACTIVE MOIETYO414PZ4LPZ2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42783-32342783-323-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
salicylic acidO414PZ4LPZACTIB

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
eb087bbb-fd4d-4a5e-bd39-057ddf32ed86a01a3ccd-d9bc-40b6-b269-cddd6d0e47c52021-12-08Adverse reactionsExact identifier
spl id: eb087bbb-fd4d-4a5e-bd39-057ddf32ed86
spl set id: a01a3ccd-d9bc-40b6-b269-cddd6d0e47c5

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.